ARCH PATHOL LAB MED:利用免疫组化和原位杂交鉴定乳腺Paget病的分子亚型

2019-02-06 MedSci MedSci原创

在大多数情况下,乳腺的Paget疾病是导管原位癌的表皮内扩散。乳腺浸润性癌的分子亚型具有预后和治疗意义,并具有特征性分布。然而目前,关于乳腺Paget病中分子亚型的分布知之甚少。本研究的目的-研究乳腺Paget病中分子亚型的分布,并将其与乳腺并发浸润癌(如果存在)进行比较。

在大多数情况下,乳腺的Paget疾病是导管原位癌的表皮内扩散。乳腺浸润性癌的分子亚型具有预后和治疗意义,并具有特征性分布。然而目前,关于乳腺Paget病中分子亚型的分布知之甚少。本研究的目的-研究乳腺Paget病中分子亚型的分布,并将其与乳腺并发浸润癌(如果存在)进行比较。

研究人员采用免疫组织化学和抗雌激素和孕激素受体,人表皮生长因子受体2HER2)和Ki-67以及HER2显色原位杂交检测48例乳腺Paget病,并对其进行了分类。然后,将结果与相关的乳腺浸润性癌的分子亚型进行比较(如果存在的话)。

结果显示,HER2亚型是乳腺Paget病最常见的亚型,其次是腔内B亚型和2例三阴性亚型。相关浸润性癌多为腔内B亚型,其次为HER2亚型和三重阴性亚型。大多数病例的Paget病与浸润性癌的分子亚型一致。

研究表明,可以在Paget病中检测到乳腺浸润性癌的分子亚型。Paget病及其相关浸润性癌的分子亚型分布不同于无相关Paget病的浸润性癌,其中HER2亚型在Paget病及相关浸润性癌中过度表达,腔内及三阴性亚型表达不足。

原始出处:

David L. Wachter, Peter W. Wachter, Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-09-22 minzju5052
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-08-13 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
    2019-08-14 yuandd
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1786065, encodeId=5de21e8606593, content=<a href='/topic/show?id=0202136e1e4' target=_blank style='color:#2F92EE;'>#Paget#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13671, encryptionId=0202136e1e4, topicName=Paget)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Sun Sep 22 03:50:00 CST 2019, time=2019-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786259, encodeId=59e91e8625989, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Aug 13 06:50:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786074, encodeId=58c61e86074ad, content=<a href='/topic/show?id=e047136e481' target=_blank style='color:#2F92EE;'>#Paget病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13674, encryptionId=e047136e481, topicName=Paget病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Wed Aug 14 13:50:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339935, encodeId=638f13399353b, content=<a href='/topic/show?id=0ec031565c3' target=_blank style='color:#2F92EE;'>#分子亚型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31565, encryptionId=0ec031565c3, topicName=分子亚型)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438909, encodeId=22d81438909b4, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609560, encodeId=a8e01609560ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 08 12:50:00 CST 2019, time=2019-02-08, status=1, ipAttribution=)]

相关资讯

Sci Rep:肺癌病理图像综合分析发现预测生存结局的肿瘤形态和边界特征

这项研究为肿瘤形态与患者预后之间的关联提供了新的见解。

ARCH PATHOL LAB MED:互联网论坛促进癌症登记员和病理学家之间的沟通?

癌症登记员应与病理学家密切合作,以确保符合报告标准。然而,许多登记员很少与病理学家接触,导致缺乏对其个人专业活动和发展的实时互动。随着癌症生物学变得越来越复杂, 为方便注册医生的个案管理,本研究开发了ATP(询问病理学家)论坛,以询问与肿瘤相关的问题,如术语、生物学、组织学分类、疾病程度、分子标记和预后因素。 所罗列的问题由ATP多学科监督委员会审核,该委员会由3名病理学家、4名癌症登

Int J Oral Max Surg: 成年人群第三磨牙的症状

本研究的目的是评估代表30岁及以上芬兰人群中第三磨牙的临床和影像学征象。

中国将打破医师执业证终生制 三大专业医师率先开展定期考核

    8月10日,第22届中国内镜医师大会在广东省中山市开幕,记者从卫生部内镜与微创医师定期考核专家委员会获悉,该委员会将首次启动全国医师终生定期统考制度,包括内镜微创、病理学、整形美容在内的三个专业将在全国率先开展定期考核。     近期在卫生部召开的“全国医师定期考核内镜与微创专业委员会成立暨第一次考试工作会议”上,内镜与微创医师